



Zenlabs Ethica Ltd.

CIN NO. : L74900CH1993PLC033112, GSTIN NO. : 03AAFCS6226G1ZL

Regd. Office : Plot No. 194-195, 3rd Floor, Industrial Area, Phase-II, Chandigarh -160 002

Tel. : 0172-465 1105, Fax : 0172-265 6855

E-mail: queries@zenlabsethica.com, Website : www.zenlabsethica.com

The Manager
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai-400001
Maharashtra.

Date: 07.08.2024

SUBJECT: Outcome of Board Meeting pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Ref: Zenlabs Ethica Limited (Scrip Code: 530697)

Dear Sir/ Madam,

Pursuant to the provisions of Regulation 30 and other applicable provisions of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, we wish to inform you that the Board of Directors of the Company has, at its meeting held today on Wednesday, August 7, 2024 at 1:00 P.M and concluded at 2:30 P.M., inter alia, approved the following:

1. The Unaudited Financial Results for the quarter ended on 30th June, 2024. We are enclosing herewith the following documents as in this respect:
 - a. Unaudited Standalone Financial Results of the Company for the quarter ended June 30, 2024.
 - b. Limited Review Report on the Unaudited Standalone Financial Results of the Company for the quarter ended June 30, 2024 issued by M/s N Kumar Chhabra and Co., Statutory Auditors of the Company.
2. Appointment of Ms. Manju Bala (M. No. A67831) as the Company Secretary & Compliance Officer of the Company w. e. f. **07 August, 2024.**
3. Appointment of Ms. Manju Bala as Nodal Officer for the purpose of co-ordination with Investor Education and Protection Fund Authority.

The following are the details:

Name	Ms. Manju Bala
Designation	Company Secretary & Compliance Officer
Postal Address	Plot No. 194-195, 3rd Floor, Industrial Area, Phase-II, Chandigarh - 160002.
Contact No.	Tel: 0172-4651105
Email id	secretarial@zenlabsethica.com

4. Re-appointment of Mr. Sanjeev Kumar as Managing Director for tenure of five years with effect from 1st September, 2024 to 31st August 2029, subject to the approval of Shareholders at the 31st Annual General Meeting of the Company.

Disclosure of information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023 is attached herewith as **Annexure- II**

You are requested to take the above mentioned information on your records.

Thanking You

Yours Truly

For **ZENLABS ETHICA LIMITED**

Sanjay Dhir
Whole Time Director
DIN: 02452461

Encl: As Above

ZENLABS ETHICA LIMITED

Corporate Identification Number: L74900CH1993PLC033112, GSTIN 03AAAFCS6226G1ZL
Registered Office: Plot No. 194-195, 3rd Floor, Industrial Area, Phase II, Chandigarh - 160 002
Telephone: 0172-465 1105, Fax: 0172-265 6855
E-mail: queries@zenlabsethica.com, Website: www.zenlabsethica.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2024

Sr. No	Particulars	(₹ in Lakhs except EPS data)			
		Quarter Ended 30-06-2024	Preceding quarter ended 31-03-2024	Corresponding quarter ended 30-06-2023	Previous year ended 31-03-2024
		(Unaudited)	(Refer note 5)	(Unaudited)	Audited
1	Revenue from Operations	1,236.26	1,532.72	1,357.23	5,856.31
2	Other Income	0.28	2.29	4.83	29.92
3	Total Income (1+2)	1,236.54	1,535.01	1,362.06	5,886.23
4	Expenditure				
	a) Purchase of stock in trade	984.87	1,005.32	1,205.51	4,441.41
	b) (Increase)/decrease in stock-in-trade	(80.42)	103.81	(164.03)	(62.64)
	c) Employees benefit expenses	112.09	111.44	103.22	445.75
	d) Finance costs	22.83	24.76	15.73	83.37
	e) Depreciation and Amortisation	31.92	32.56	32.31	129.44
	f) Other Expenditure	158.09	236.26	159.50	790.75
	Total Expenses	1,229.38	1,514.15	1,352.23	5,828.08
5	Profit before Exceptional & Extraordinary Items (3-4)	7.16	20.87	9.83	58.15
6	Exceptional Items	-	-	-	-
7	Profit Before Tax (5-6)	7.16	20.87	9.83	58.15
8	Tax Expenses				
	a) Current Tax	2.00	10.26	2.38	20.59
	b) MAT Credit entitlement	-	-	-	-
	c) Deferred Tax	0.99	(4.66)	0.81	(4.56)
9	Profit(+)/ Loss(-) for the period (7-8)	4.18	15.27	6.64	42.12
10	Other Comprehensive Income				
	Items that will not be reclassified to profit or loss				
	Re-measurement of the net defined benefit plans	1.60	0.30	(2.04)	(0.23)
	Tax on above	(0.40)	(0.07)	0.51	0.06
11	Total Other comprehensive Income, net of tax	1.19	0.23	(1.53)	(0.17)
12	Total comprehensive Income for the period	5.37	15.49	5.12	41.95
13	Paid up equity share capital (Face Value of ₹ 10/- each per share)	651.00	651.00	651.00	651.00
14	Basic and diluted Earning Per Share (EPS) after Extra Ordinary Items				
	-Basic (in ₹)	0.06	0.23	0.10	0.65
	-Diluted (in ₹)	0.06	0.23	0.10	0.65

NOTES :

- The above financial results for the quarter ended 30th June, 2024 have been reviewed by the Audit Committee and were approved and taken on record by the Board of Directors in their respective meeting held on 7th August, 2024. The statutory auditors of the Company have expressed an unmodified opinion in audit report on these on these financial results.
- The Standalone financial results are prepared in accordance with Indian Accounting Standards ("Ind AS"), the provisions of the Companies Act, 2013 ("the Act"), as applicable and guidelines issued by the Securities and Exchange Board of India ("SEBI"). The Ind AS are prescribed under Section 133 of the Act read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.
- The Company is considered to be a single segment company engaged in the trading of pharmaceuticals formulation. Consequently, the Company has, in its primary segment, only one reportable business segment. Accordingly, there are no separate reportable segments as required under Ind AS 108 "Operating Segment".
- Previous period figures have been re-grouped/ re-classified, wherever necessary, to conform to current period's classifications.
- Figures for the quarter ended 31 March 2024 are the balancing figures between audited figures for the full financial year and the reviewed year to date figures upto the third quarter of the financial year.

By order of Board
for Zenlabs Ethica Limited

Place: Chandigarh
Date: 7th August, 2024

Sanjay Dhir
DIN: 02452461
Whole Time Director

Independent Auditor's Review Report on Unaudited Quarterly Financial Results of Zenlabs Ethica Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

To

The Board of Directors
Zenlabs Ethica Limited

1. We have reviewed the accompanying statement of unaudited financial results ("the statement") of **Zenlabs Ethica Limited** ("the Company") for the quarter ended June 30, 2024, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including relevant circulars issued by the Securities and Exchange Board of India ("SEBI") from time to time.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under Section 133 of Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for the financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters and might be identified in an Audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable Indian accounting standards specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

for **N Kumar Chhabra and Co.**

Chartered Accountants

ICAI Firm Registration Number 00837N

ASHISH

CHHABRA

Digitally signed by
ASHISH CHHABRA
Date: 2024.08.07
14:19:32 +05'30'

CA. Ashish Chhabra

FCA., Partner

Membership Number 507083

UDIN: 24507083BKBLZZ5975

Place: Chandigarh

Date: 7th August 2024